CDK9 inhibitor HH1
CDK9 inhibitor HH1 is a potent and selectively CDK9 inhibitor. CDK9 inhibitor HH1 inhibits the transcription of CDK. CDK9 inhibitor HH1 can be used in research of cancer[1].
Product Specifications
CAS Number
[204188-41-0]
UNSPSC
12352005
Target
CDK
Type
Reference compound
Related Pathways
Cell Cycle/DNA Damage
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/cdk9-inhibitor-hh1.html
Purity
99.69
Solubility
DMSO : 50 mg/mL (ultrasonic)
Smiles
O=C(C1=C(N)N=C(NC(C)C)S1)C2=CC=CC=C2
Molecular Formula
C13H15N3OS
Molecular Weight
261.34
References & Citations
[1]Pandey S, et, al. Selective CDK9 Inhibition by Natural Compound Toyocamycin in Cancer Cells. Cancers (Basel) . 2022 Jul 8;14 (14) :3340.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
CDK9
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
